Nucelion Therapeutics, Pandorum to develop 2 eye therapies
In short
Nucelion Therapeutics and Pandorum Technologies will work on two eye-care projects. The projects are for advanced keratopathy and wet age-related macular degeneration.
The reporting does not say how much money is involved or when results may come. It is not clear yet what the immediate business impact will be.
What the reporting says
Nucelion Therapeutics and Pandorum Technologies will take up two ophthalmology projects focused on investigational therapies for advanced keratopathy and wet age-related macular degeneration. The reporting does not state funding, timelines or clinical stage beyond the projects being investigational. The immediate commercial or regulatory impact was not stated in the available reporting.
Why it matters
Nucelion Therapeutics and Pandorum Technologies are taking up two ophthalmology projects aimed at investigational therapies for advanced keratopathy and wet AMD. That suggests work in advanced eye disease treatment, but the source does not give funding, timelines or development milestones. Any near-term impact on the companies, patients or partners remains unknown from the available reporting.